Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases
- PMID: 22417806
- DOI: 10.1016/j.ijrobp.2011.12.093
Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases
Abstract
Purpose: To determine the clinical value of two novel molecular imaging techniques: (11)C-choline positron emission tomography (PET)/computed tomography (CT) and ferumoxtran-10 enhanced magnetic resonance imaging (magnetic resonance lymphography [MRL]) for lymph node (LN) treatment in prostate cancer (PCa) patients. Therefore, we evaluated the ability of PET/CT and MRL to assess the number, size, and location of LN metastases in patients with primary or recurrent PCa.
Methods and materials: A total of 29 patients underwent MRL and PET/CT for LN evaluation. The MRL and PET/CT data were analyzed independently. The number, size, and location of the LN metastases were determined. The location was described as within or outside the standard clinical target volume for elective pelvic irradiation as defined by the Radiation Therapy Oncology Group. Subsequently, the results from MRL and PET/CT were compared.
Results: Of the 738 LNs visible on MRL, 151 were positive in 23 of 29 patients. Of the 132 LNs visible on PET/CT, 34 were positive in 13 of 29 patients. MRL detected significantly more positive LNs (p < 0.001) in more patients than PET/CT (p = 0.002). The mean diameter of the detected suspicious LNs on MRL was significantly smaller than those detected by PET/CT, 4.9 mm and 8.4 mm, respectively (p < 0.0001). In 14 (61%) of 23 patients, suspicious LNs were found outside the clinical target volume with MRL and in 4 (31%) of 13 patients with PET/CT.
Conclusion: In patients with PCa, both molecular imaging techniques, MRL and (11)C-choline PET/CT, can detect LNs suspicious for metastasis, irrespective of the existing size and shape criteria for CT and conventional magnetic resonance imaging. On MRL and PET/CT, 61% and 31% of the suspicious LNs were located outside the conventional clinical target volume. Therefore, these techniques could help to individualize treatment selection and enable image-guided radiotherapy for patients with PCa LN metastases.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S28-35. doi: 10.1007/s00259-013-2404-0. Epub 2013 Apr 11. Eur J Nucl Med Mol Imaging. 2013. PMID: 23576101 Review.
-
[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x. Epub 2012 Apr 23. BJU Int. 2012. PMID: 22520686
-
[Diagnostic relevance of choline-PET / CT in patients with prostate cancer].Aktuelle Urol. 2012 Jan;43(1):49-54. doi: 10.1055/s-0031-1271553. Epub 2011 Jul 18. Aktuelle Urol. 2012. PMID: 21769763 Review. German.
-
Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.Eur Urol. 2011 Jul;60(1):125-30. doi: 10.1016/j.eururo.2011.01.015. Epub 2011 Jan 18. Eur Urol. 2011. PMID: 21292388
-
Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancer.Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):175-83. doi: 10.1016/j.ijrobp.2010.09.023. Epub 2010 Nov 13. Int J Radiat Oncol Biol Phys. 2012. PMID: 21075555
Cited by
-
Functional roles of magnetic nanoparticles for the identification of metastatic lymph nodes in cancer patients.J Nanobiotechnology. 2023 Sep 21;21(1):337. doi: 10.1186/s12951-023-02100-0. J Nanobiotechnology. 2023. PMID: 37735449 Free PMC article. Review.
-
The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nat Rev Urol. 2022 Aug;19(8):475-493. doi: 10.1038/s41585-022-00618-w. Epub 2022 Jul 4. Nat Rev Urol. 2022. PMID: 35789204 Review.
-
Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study.Cancers (Basel). 2021 Jul 31;13(15):3868. doi: 10.3390/cancers13153868. Cancers (Basel). 2021. PMID: 34359768 Free PMC article.
-
Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients.J Nucl Med. 2021 Sep 1;62(9):1258-1263. doi: 10.2967/jnumed.120.258541. Epub 2021 Jan 30. J Nucl Med. 2021. PMID: 33517328 Free PMC article.
-
Magnetic resonance imaging at ultra-high magnetic field strength: An in vivo assessment of number, size and distribution of pelvic lymph nodes.PLoS One. 2020 Jul 31;15(7):e0236884. doi: 10.1371/journal.pone.0236884. eCollection 2020. PLoS One. 2020. PMID: 32735614 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical